Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables - Accured (2016 - 2025)

Celldex Therapeutics has reported Revenue - Other over the past 4 years, most recently at $2.3 million for Q1 2013.

  • Quarterly results put Revenue - Other at $2.3 million for Q1 2013, changed 0.43% from a year ago — trailing twelve months through Dec 2013 was $2.3 million (down 78.34% YoY), and the annual figure for FY2013 was $2.3 million, down 78.34%.
  • Receivables - Accured for Q4 2025 was $4.4 million at Celldex Therapeutics, down from $6.0 million in the prior quarter.
  • Over the last five years, Receivables - Accured for CLDX hit a ceiling of $6.2 million in Q2 2025 and a floor of $300000.0 in Q2 2021.
  • Median Receivables - Accured over the past 5 years was $1.3 million (2021), compared with a mean of $2.7 million.
  • Biggest five-year swings in Revenue - Other: soared 123.53% in 2011 and later decreased 6.31% in 2012.
  • Celldex Therapeutics' Revenue - Other stood at $1.7 million in 2010, then skyrocketed by 42.82% to $2.4 million in 2011, then skyrocketed by 50.59% to $3.6 million in 2012, then tumbled by 34.27% to $2.3 million in 2013.
  • The last three reported values for Revenue - Other were $2.3 million (Q1 2013), $3.6 million (Q4 2012), and $3.0 million (Q3 2012) per Business Quant data.